1
|
M. GB, Jain R, Shah SS, Shaikh FA. Relapsed Plasmablastic Lymphoma in an HIV-Infected Patient—Experience of High-Dose Chemotherapy with Autologous Stem Cell Rescue: A Case Report with Review of Literature. Indian J Med Paediatr Oncol 2022. [DOI: 10.1055/s-0042-1742455] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Abstract
AbstractPlasmablastic lymphoma (PBL) is a subtype of non-Hodgkin lymphoma with dismal outcome despite multidrug chemotherapy regimen leading to high rates of disease recurrence. High-dose chemotherapy with autologous stem cell rescue (HDCT/ASCR) is an effective salvage therapy in patients with chemo-sensitive human immunodeficiency virus (HIV)-associated non-Hodgkin lymphoma. We report a case of 38 years old male with relapsed PBL associated with underlying HIV infection, who underwent HDCT/ASCR. He presented with low-grade fever and abdominal discomfort. He was evaluated with fluorodeoxyglucose positron emission tomography scan followed by omental biopsy that confirmed disease relapse. He received second-line therapy containing bortezomib and daratumumab and achieved remission (CR2). Subsequently, he underwent HDCT/ASCR. He has been clinically asymptomatic in good general condition having disease-free survival of 18 months after HDCT/ASCR. Our objective of presenting this case report is its complexity from presentation, diagnosis, and treatment. We take this opportunity to review the epidemiology and clinicopathological characteristics of PBL, as well as discuss the advancements in therapeutic options of this challenging disease.
Collapse
Affiliation(s)
- Ganapathi Bhat M.
- Department of Medical Oncology & BMT, Jaslok Hospital & Research Centre, Mumbai, Maharashtra, India
| | - Reetu Jain
- Department of Medical Oncology & BMT, Jaslok Hospital & Research Centre, Mumbai, Maharashtra, India
| | - Samir S. Shah
- Department of Hemato Oncology & BMT, Jaslok Hospital & Research Centre, Mumbai, Maharashtra, India
| | - Fahad Afzal Shaikh
- Department of Medical Oncology & BMT, Jaslok Hospital & Research Centre, Mumbai, Maharashtra, India
| |
Collapse
|
2
|
Hosoi H, Mushino T, Nakashima K, Kuriyama K, Tamura S, Murata S, Imadome KI, Ohshima K, Sonoki T. Composite Epstein-Barr Virus-associated T-lymphoblastic and Peripheral T-cell Lymphomas: A Clonal Study. Intern Med 2021; 60:2119-2123. [PMID: 33551410 PMCID: PMC8313923 DOI: 10.2169/internalmedicine.6572-20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
A 30-year-old woman was diagnosed with T-lymphoblastic lymphoma (T-LBL) that harbored a clonal Epstein-Barr virus (EBV) genome. At relapse, axillary lymph node adenopathy, which was diagnosed as peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), was detected. Southern blot analyses of the T-cell receptor and EBV genome revealed that the T-LBL and PTCL-NOS were clonally identical. We previously showed that CD21 acted as an entry molecule that allowed EBV into the patient's T-LBL cells. Interestingly, the PTCL-NOS cells lacked CD21 expression. Our case suggests that EBV might infect immature CD21-positive T-cells, and CD21-negative PTCL-NOS might subsequently arise through phenotypic changes.
Collapse
Affiliation(s)
- Hiroki Hosoi
- Department of Hematology/Oncology, Wakayama Medical University, Japan
| | - Toshiki Mushino
- Department of Hematology/Oncology, Wakayama Medical University, Japan
| | | | - Kodai Kuriyama
- Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Japan
| | - Shinobu Tamura
- Department of Hematology/Oncology, Wakayama Medical University, Japan
| | - Shogo Murata
- Department of Hematology/Oncology, Wakayama Medical University, Japan
| | - Ken-Ichi Imadome
- Department of Advanced Medicine for Infections, National Center for Child Health and Development, Japan
| | - Koichi Ohshima
- Department of Pathology, Kurume University School of Medicine, Japan
| | - Takashi Sonoki
- Department of Hematology/Oncology, Wakayama Medical University, Japan
| |
Collapse
|
3
|
Li M, Shen Y, Chen Y, Gao H, Zhou J, Wang Q, Fan C, Zhang W, Li J, Cong H, Gu J, Gan Y, Tu H. Characterization of hepatitis B virus infection and viral DNA integration in non-Hodgkin lymphoma. Int J Cancer 2020; 147:2199-2209. [PMID: 32350851 DOI: 10.1002/ijc.33027] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2020] [Revised: 04/02/2020] [Accepted: 04/17/2020] [Indexed: 12/12/2022]
Abstract
Hepatitis B virus (HBV) infection has been reported to be associated with non-Hodgkin lymphoma (NHL). However, the evidence is limited to the seroepidemiological study. There is a lack of evidence showing the HBV infection and integration in NHL cells. Here, we reported that in the Shanghai area, the positive rates of serum HBsAg (OR: 3.11; 95% CI: 2.20-4.41) and HBeAg (OR: 3.99; 95% CI: 1.73-9.91) were significantly higher in patients with NHL. HBsAg, HBcAg and HBV DNA were detected in 34.4%, 45.2% and 47.0% of the NHL tissues, respectively. Furthermore, by using a high-throughput viral integration detection approach (HIVID), integrated HBV DNA was identified from 50% (6/12) HBV-related NHL tissues. There were a total of 313 HBV integration sites isolated from the NHL tissues, among which four protein-coding genes (FAT2, SETX, ITGA10 and CD63) were interrupted by HBV DNA in their exons. Seven HBV preferential target genes (ANKS1B, HDAC4, EGFLAM, MAN1C1, XKR6, ZBTB38 and CCDC91) showed significantly altered expression levels in NHL, suggesting a potential role of these genes in NHL development. Taken together, HBV integration is a common phenomenon in NHL. This finding opens up a new direction of research into the mechanistic link between HBV infection and NHL.
Collapse
Affiliation(s)
- Mengge Li
- State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Yuling Shen
- State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,Department of Head and Neck Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Yiming Chen
- Department of Pathology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Haifeng Gao
- Department of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China
| | - Jiaqin Zhou
- Department of Head and Neck Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Qing Wang
- State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Chunsun Fan
- State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,Department of etiology, Qidong People's Hospital/Qidong Liver Cancer Institute, Qidong, China
| | - Wei Zhang
- State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Jin Li
- State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Hui Cong
- State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Jinyang Gu
- Department of Transplantation, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Yu Gan
- State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Hong Tu
- State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| |
Collapse
|
4
|
Mechanistic Insights into Chemoresistance Mediated by Oncogenic Viruses in Lymphomas. Viruses 2019; 11:v11121161. [PMID: 31888174 PMCID: PMC6950054 DOI: 10.3390/v11121161] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2019] [Revised: 12/09/2019] [Accepted: 12/12/2019] [Indexed: 12/17/2022] Open
Abstract
Viral lymphomagenesis induced by infection with oncogenic viruses, such as Kaposi’s sarcoma associated herpesvirus (KSHV), Epstein–Barr virus (EBV) and human T-cell leukemia virus (HTLV-1), represents a group of aggressive malignancies with a diverse range of pathological features. Combined chemotherapy remains the standard of care for these virus-associated lymphomas; however, frequent chemoresistance is a barrier to achieving successful long-term disease-free survival. There is increasing evidence that indicates virus-associated lymphomas display more resistance to cytotoxic chemotherapeutic agents than that observed in solid tumors. Although the tumor microenvironment and genetic changes, such as key oncogene mutations, are closely related to chemoresistance, some studies demonstrate that the components of oncogenic viruses themselves play pivotal roles in the multidrug chemoresistance of lymphoma cells. In this review, we summarize recent advances in the understanding of the mechanisms through which oncogenic viruses mediate lymphoma cell chemoresistance, with a particular focus on KSHV and EBV, two major oncogenic viruses. We also discuss the current challenges to overcome these obstacles in the treatment of virus-associated lymphomas.
Collapse
|
5
|
Fernandes M, Teixeira AL, Medeiros R. The opportunistic effect of exosomes on Non-Hodgkin Lymphoma microenvironment modulation. Crit Rev Oncol Hematol 2019; 144:102825. [PMID: 31734546 DOI: 10.1016/j.critrevonc.2019.102825] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2019] [Revised: 10/20/2019] [Accepted: 10/22/2019] [Indexed: 12/14/2022] Open
Abstract
There has been a shift in the paradigm of Non-Hodgkin lymphomas, changing from the classical genetic aberration-based model to a more complex and dynamic model involving tumor microenvironment interactions. In this instance, exosomes have emerged as important mediators in intercellular communication by providing survival and proliferation signals, licensing immune evasion and acquisition of drug resistance. The capability to transfer molecular cargo made exosomes a focus of research to understand cancer pathogenesis and its progression pathways. Several studies identified exosomes transporting tumor-released components in peripheral blood and focused on understanding their clinical relevance in the diagnosis, prognostic and in monitoring cancer progression. Moreover, due to their biophysical properties and physiological function, exosomes have drawn attention as potential therapeutic target and drug delivery vehicles. This review will discuss the function of exosomes in Non-Hodgkin lymphomagenesis, highlight their potential as diagnosis and prognosis biomarkers, and as new therapeutic opportunities in lymphoma management.
Collapse
Affiliation(s)
- Mara Fernandes
- Molecular Oncology and Viral Pathology Group, IPO-Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO-Porto), Rua Dr António Bernardino de Almeida, 4200-072 Porto, Portugal; Faculty of Medicine, University of Porto (FMUP), Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal; Research Department, LPCC-Portuguese League against Cancer- Northern Branch (Liga Portuguesa Contra o Cancro-Núcleo Regional do Norte), Estrada Interior da Circunvalação 6657, 4200-172 Porto, Portugal
| | - Ana Luísa Teixeira
- Molecular Oncology and Viral Pathology Group, IPO-Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO-Porto), Rua Dr António Bernardino de Almeida, 4200-072 Porto, Portugal
| | - Rui Medeiros
- Molecular Oncology and Viral Pathology Group, IPO-Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO-Porto), Rua Dr António Bernardino de Almeida, 4200-072 Porto, Portugal; Faculty of Medicine, University of Porto (FMUP), Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal; Research Department, LPCC-Portuguese League against Cancer- Northern Branch (Liga Portuguesa Contra o Cancro-Núcleo Regional do Norte), Estrada Interior da Circunvalação 6657, 4200-172 Porto, Portugal; CEBIMED, Faculty of Health Sciences, Fernando Pessoa University, Praça de 9 de Abril 349, 4249-004 Porto, Portugal.
| |
Collapse
|
6
|
Olivier-Gougenheim L, Dijoud F, Traverse-Glehen A, Benezech S, Bertrand Y, Latour S, Frobert E, Domenech C. Aggressive large B-cell lymphoma triggered by a parvovirus B19 infection in a previously healthy child. Hematol Oncol 2019; 37:483-486. [PMID: 31408541 DOI: 10.1002/hon.2665] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2019] [Revised: 07/17/2019] [Accepted: 08/07/2019] [Indexed: 11/07/2022]
Abstract
In absence of red blood cells disease or immune defect, parvovirus B19 (PVB-19) is usually considered as a benign condition. Here, we report the case of a 10-year-old boy, previously healthy, presenting with a PVB-19 infection revealed by a bicytopenia and a voluminous axillary adenopathy. Pathophysiology examination showed reactional lymphoid population. Nine months later and in the absence of remission, a new biopsy of the same adenopathy revealed a Hodgkin lymphoma with area of T-cell rich aggressive large B-cell lymphoma. This case suggests PVB-19 as potential trigger of this malignant childhood hemopathy. Although no definitive conclusion can be drawn, our clinical case questions the role of PVB-19 in lymphomagenesis.
Collapse
Affiliation(s)
- Laura Olivier-Gougenheim
- Institute of Pediatric Hematology and Oncology, Hospices Civils de Lyon, Claude Bernard Lyon I University, Lyon, France
| | - Frederique Dijoud
- Anatomy-Cytology-Pathology Department, Women-Mother and Child Hospital, Hospices Civils de Lyon, Lyon, France
| | - Alexandra Traverse-Glehen
- Anatomy-Pathology Unit, Lyon Sud Hospital, Hospices Civils de Lyon, Claude Bernard Lyon I University, Lyon, France
| | - Sarah Benezech
- Institute of Pediatric Hematology and Oncology, Center Léon Bernard, Lyon, France
| | - Yves Bertrand
- Institute of Pediatric Hematology and Oncology, Hospices Civils de Lyon, Claude Bernard Lyon I University, Lyon, France
| | - Sylvain Latour
- Laboratory of Lymphocyte Activation and Susceptibility to EBV, INSERM UMR 1163-Imagine Institute, Paris, France
| | - Emilie Frobert
- Virology Laboratory, Infectious Agent Institute, Croix-Rousse Hospital, Hospices Civils de Lyon, Claude Bernard Lyon I University, Virpath, CIRI, INSERM U1111, CNRS 5308, ENS Lyon, Lyon, France
| | - Carine Domenech
- Institute of Pediatric Hematology and Oncology, Hospices Civils de Lyon, Claude Bernard Lyon I University, Lyon, France
| |
Collapse
|
7
|
Lopez A, Abrisqueta P. Plasmablastic lymphoma: current perspectives. BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY 2018; 8:63-70. [PMID: 31360094 PMCID: PMC6467349 DOI: 10.2147/blctt.s142814] [Citation(s) in RCA: 60] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Plasmablastic lymphoma (PbL) is a rare and aggressive B-cell malignancy with large neoplastic cells, most of them resembling plasmablasts that have a CD20-negative phenotype. Although initially described as being associated with HIV, over the years it has also been identified in patients with solid organ transplant and immunocompetent patients. Little is known about molecular basis that drives PbL, and still its diagnosis remains challenging given its rarity. However, proper recognition of its clinical characteristics, localization, and morphological features can establish a correct diagnosis of PbL within the spectrum of CD20-negative large B-cell lymphomas (LBCLs). PbL is characterized by CD20 and PAX5 negativity together with the expression of CD38, CD138, MUM1/IRF4, Blimp1, and XBP1 plasmacytic differentiation markers. It is usually associated with Epstein–Barr virus infections, and MYC gene rearrangements. PbL should be carefully differentiated from other CD20-negative B-cell neoplasms, ie, primary effusion lymphoma, anaplastic lymphoma kinase-positive (ALK) large B-cell lymphoma, and LBCL in human herpesvirus 8-associated multicentric Castleman disease. Despite our improved understanding of this disease, its prognosis remains dismal with short overall survival. There is no standard of care for this entity. Several chemotherapy combinations have been used with hardly any differences on its outcome. Thus, new approaches with the addition of novel molecules are needed to overcome its poor prognosis. Our current understanding and knowledge of PbL relies primarily on case reports and small case series. In this review, we revise through an extensive literature search, the clinical and biological characteristics of this entity, and the potential therapeutic options.
Collapse
Affiliation(s)
- Andres Lopez
- Lymphoma Unit, Department of Hematology, Vall d'Hebron University Hospital, Barcelona, Spain,
| | - Pau Abrisqueta
- Department of Hematology, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain
| |
Collapse
|
8
|
Hernández DM, Valderrama S, Gualtero S, Hernández C, López M, Herrera MV, Solano J, Fiorentino S, Quijano S. Loss of T-Cell Multifunctionality and TCR-Vβ Repertoire Against Epstein-Barr Virus Is Associated With Worse Prognosis and Clinical Parameters in HIV + Patients. Front Immunol 2018; 9:2291. [PMID: 30337929 PMCID: PMC6180205 DOI: 10.3389/fimmu.2018.02291] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2018] [Accepted: 09/14/2018] [Indexed: 12/16/2022] Open
Abstract
Epstein-Barr virus (EBV) is an oncogenic virus associated with the development of aggressive and poor-prognosis B-cell lymphomas in patients infected with human immunodeficiency virus (HIV+ patients). The most important risk factors for these malignancies include immune dysfunction, chronic immune activation, and loss of T-cell receptor (TCR) repertoire. The combination of all these factors can favor the reactivation of EBV, malignant cell transformation, and clinical progression toward B-cell lymphomas. The overarching aim of this study was to evaluate the frequency, phenotype, functionality, and distribution of TCR clonotypes for EBV-specific T-cell subpopulations in HIV+ patients at different clinical stages and for HIV+ patients with B-cell lymphoma, as well as to establish their association with clinical variables of prognostic value. Factors were studied in 56 HIV+ patients at different clinical stages and in six HIV+ subjects with diagnosed B-cell lymphoma. We found a significant decrease in all subpopulations of EBV-specific CD4+ T cells from HIV+ patients at stage 3 and with B-cell lymphoma. EBV-specific effector CD8+ T cells, particularly effector memory cells, were also reduced in HIV+ patients with B-cell lymphoma. Interestingly, these cells were unable to produce IFN-γ and lacked multifunctionality in HIV+ patients. The TCR-Vβ repertoire, which is key for protection against EBV in healthy individuals, was less diverse in HIV+ patients due to a lower frequency of TCR-Vβ2+, Vβ4+, Vβ7.1+, Vβ9+, Vβ13.6+, Vβ14+, Vβ17+, Vβ22+ CD4+, Vβ14+, and Vβ17+ CD8+ T cells. HIV+ patients with positive plasma EBV loads (EBV+HIV+) had a noteworthy decrease in the levels of both TNF-α+ and multifunctional TNF-α+/IL-2+ and TNF-α+/IFN-γ+ CD8+ T cells. Altogether, our findings demonstrate that HIV+ patients have significant alterations in the immune response to EBV (poor-quality immunity) that can favor viral reactivation, escalating the risk for developing EBV-associated B-cell lymphomas.
Collapse
Affiliation(s)
- Diana M Hernández
- Grupo de Inmunobiología y Biología Celular, Departamento de Microbiología, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá, Colombia
| | - Sandra Valderrama
- Grupo de Investigación en Enfermedades Infecciosas, Hospital Universitario San Ignacio, Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá, Colombia
| | - Sandra Gualtero
- Grupo de Investigación en Enfermedades Infecciosas, Hospital Universitario San Ignacio, Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá, Colombia
| | - Catalina Hernández
- Grupo de Investigación en Enfermedades Infecciosas, Hospital Universitario San Ignacio, Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá, Colombia
| | - Marcos López
- Grupo de Investigación Biomédica Traslacional, Fundación Cardiovascular de Colombia, Floridablanca, Colombia
| | | | - Julio Solano
- Servicio de Hematología Hospital Universitario San Ignacio, Bogotá, Colombia
| | - Susana Fiorentino
- Grupo de Inmunobiología y Biología Celular, Departamento de Microbiología, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá, Colombia
| | - Sandra Quijano
- Grupo de Inmunobiología y Biología Celular, Departamento de Microbiología, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá, Colombia
| |
Collapse
|
9
|
Castillo JJ. Viral lymphomagenesis: beyond the usual suspects. Br J Haematol 2018; 182:617-618. [PMID: 29808932 DOI: 10.1111/bjh.15414] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Jorge J Castillo
- Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| |
Collapse
|
10
|
Xu B, Wang T. Intimate cross-talk between cancer cells and the tumor microenvironment of B-cell lymphomas: The key role of exosomes. Tumour Biol 2017; 39:1010428317706227. [PMID: 28618932 DOI: 10.1177/1010428317706227] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Affiliation(s)
- Biyu Xu
- Department of Hematology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
| | - Ting Wang
- Department of Hematology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
| |
Collapse
|
11
|
Kaye S, Wang W, Miller C, McLuckie A, Beatty JA, Grant CK, VandeWoude S, Bielefeldt-Ohmann H. Role of Feline Immunodeficiency Virus in Lymphomagenesis--Going Alone or Colluding? ILAR J 2017; 57:24-33. [PMID: 27034392 DOI: 10.1093/ilar/ilv047] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Feline immunodeficiency virus (FIV) is a naturally occurring lentivirus of domestic and nondomestic feline species. Infection in domestic cats leads to immune dysfunction via mechanisms similar to those caused by human immunodeficiency virus (HIV) and, as such, is a valuable natural animal model for acquired immunodeficiency syndrome (AIDS) in humans. An association between FIV and an increased incidence of neoplasia has long been recognized, with frequencies of up to 20% in FIV-positive cats recorded in some studies. This is similar to the rate of neoplasia seen in HIV-positive individuals, and in both species neoplasia typically requires several years to arise. The most frequently reported type of neoplasia associated with FIV infection is lymphoma. Here we review the possible mechanisms involved in FIV lymphomagenesis, including the possible involvement of coinfections, notably those with gamma-herpesviruses.
Collapse
Affiliation(s)
- Sarah Kaye
- Sarah Kaye, BVSc, is a small animal clinician with the Animal Welfare League Qld Inc. in The Gold Coast, Queensland, Australia. Wenqi Wang, BVSc, PhD, is a postdoctoral fellow affiliated with the School of Veterinary Science at University of Queensland at Gatton in Australia. Craig Miller, DVM, is a postdoctoral fellow in the Department of Microbiology, Immunology & Pathology at Colorado State University in FortCollins, Colorado. Alicia McLuckie, BVSc, is a PhD candidate in the Faculty of Veterinary Science at the University of Sydney in NSW, Australia, Julia A. Beatty, BSc, BVetMed, PhD, FANZCVs (feline med), is a professor in the Faculty of Veterinary Science at the University of Sydney in NSW, Australia. Chris K. Grant, PhD, DSc, is founder and CEO of Custom Monoclonals International Corp. in West Sacramento, California. Sue VandeWoude, DVM, MS, DACLAM, is a professor in the Department of Microbiology, Immunology & Pathology at Colorado State University and Associate Dean for Research in the College of Veterinary & Biomedical Sciences at Colorado State University in Fort Collins, Colorado. Helle Bielefeldt-Ohmann, DVM, PhD, is a senior lecturer in the School of Veterinary Science at the University of Queensland at Gatton, an affiliate senior lecturer in the School of Chemistry & Molecular Biosciences at the University of Queensland at St. Lucia, and an investigator at the Australian Infectious Diseases Research Centre at the University of Queensland in St. Lucia, Australia
| | - Wenqi Wang
- Sarah Kaye, BVSc, is a small animal clinician with the Animal Welfare League Qld Inc. in The Gold Coast, Queensland, Australia. Wenqi Wang, BVSc, PhD, is a postdoctoral fellow affiliated with the School of Veterinary Science at University of Queensland at Gatton in Australia. Craig Miller, DVM, is a postdoctoral fellow in the Department of Microbiology, Immunology & Pathology at Colorado State University in FortCollins, Colorado. Alicia McLuckie, BVSc, is a PhD candidate in the Faculty of Veterinary Science at the University of Sydney in NSW, Australia, Julia A. Beatty, BSc, BVetMed, PhD, FANZCVs (feline med), is a professor in the Faculty of Veterinary Science at the University of Sydney in NSW, Australia. Chris K. Grant, PhD, DSc, is founder and CEO of Custom Monoclonals International Corp. in West Sacramento, California. Sue VandeWoude, DVM, MS, DACLAM, is a professor in the Department of Microbiology, Immunology & Pathology at Colorado State University and Associate Dean for Research in the College of Veterinary & Biomedical Sciences at Colorado State University in Fort Collins, Colorado. Helle Bielefeldt-Ohmann, DVM, PhD, is a senior lecturer in the School of Veterinary Science at the University of Queensland at Gatton, an affiliate senior lecturer in the School of Chemistry & Molecular Biosciences at the University of Queensland at St. Lucia, and an investigator at the Australian Infectious Diseases Research Centre at the University of Queensland in St. Lucia, Australia
| | - Craig Miller
- Sarah Kaye, BVSc, is a small animal clinician with the Animal Welfare League Qld Inc. in The Gold Coast, Queensland, Australia. Wenqi Wang, BVSc, PhD, is a postdoctoral fellow affiliated with the School of Veterinary Science at University of Queensland at Gatton in Australia. Craig Miller, DVM, is a postdoctoral fellow in the Department of Microbiology, Immunology & Pathology at Colorado State University in FortCollins, Colorado. Alicia McLuckie, BVSc, is a PhD candidate in the Faculty of Veterinary Science at the University of Sydney in NSW, Australia, Julia A. Beatty, BSc, BVetMed, PhD, FANZCVs (feline med), is a professor in the Faculty of Veterinary Science at the University of Sydney in NSW, Australia. Chris K. Grant, PhD, DSc, is founder and CEO of Custom Monoclonals International Corp. in West Sacramento, California. Sue VandeWoude, DVM, MS, DACLAM, is a professor in the Department of Microbiology, Immunology & Pathology at Colorado State University and Associate Dean for Research in the College of Veterinary & Biomedical Sciences at Colorado State University in Fort Collins, Colorado. Helle Bielefeldt-Ohmann, DVM, PhD, is a senior lecturer in the School of Veterinary Science at the University of Queensland at Gatton, an affiliate senior lecturer in the School of Chemistry & Molecular Biosciences at the University of Queensland at St. Lucia, and an investigator at the Australian Infectious Diseases Research Centre at the University of Queensland in St. Lucia, Australia
| | - Alicia McLuckie
- Sarah Kaye, BVSc, is a small animal clinician with the Animal Welfare League Qld Inc. in The Gold Coast, Queensland, Australia. Wenqi Wang, BVSc, PhD, is a postdoctoral fellow affiliated with the School of Veterinary Science at University of Queensland at Gatton in Australia. Craig Miller, DVM, is a postdoctoral fellow in the Department of Microbiology, Immunology & Pathology at Colorado State University in FortCollins, Colorado. Alicia McLuckie, BVSc, is a PhD candidate in the Faculty of Veterinary Science at the University of Sydney in NSW, Australia, Julia A. Beatty, BSc, BVetMed, PhD, FANZCVs (feline med), is a professor in the Faculty of Veterinary Science at the University of Sydney in NSW, Australia. Chris K. Grant, PhD, DSc, is founder and CEO of Custom Monoclonals International Corp. in West Sacramento, California. Sue VandeWoude, DVM, MS, DACLAM, is a professor in the Department of Microbiology, Immunology & Pathology at Colorado State University and Associate Dean for Research in the College of Veterinary & Biomedical Sciences at Colorado State University in Fort Collins, Colorado. Helle Bielefeldt-Ohmann, DVM, PhD, is a senior lecturer in the School of Veterinary Science at the University of Queensland at Gatton, an affiliate senior lecturer in the School of Chemistry & Molecular Biosciences at the University of Queensland at St. Lucia, and an investigator at the Australian Infectious Diseases Research Centre at the University of Queensland in St. Lucia, Australia
| | - Julia A Beatty
- Sarah Kaye, BVSc, is a small animal clinician with the Animal Welfare League Qld Inc. in The Gold Coast, Queensland, Australia. Wenqi Wang, BVSc, PhD, is a postdoctoral fellow affiliated with the School of Veterinary Science at University of Queensland at Gatton in Australia. Craig Miller, DVM, is a postdoctoral fellow in the Department of Microbiology, Immunology & Pathology at Colorado State University in FortCollins, Colorado. Alicia McLuckie, BVSc, is a PhD candidate in the Faculty of Veterinary Science at the University of Sydney in NSW, Australia, Julia A. Beatty, BSc, BVetMed, PhD, FANZCVs (feline med), is a professor in the Faculty of Veterinary Science at the University of Sydney in NSW, Australia. Chris K. Grant, PhD, DSc, is founder and CEO of Custom Monoclonals International Corp. in West Sacramento, California. Sue VandeWoude, DVM, MS, DACLAM, is a professor in the Department of Microbiology, Immunology & Pathology at Colorado State University and Associate Dean for Research in the College of Veterinary & Biomedical Sciences at Colorado State University in Fort Collins, Colorado. Helle Bielefeldt-Ohmann, DVM, PhD, is a senior lecturer in the School of Veterinary Science at the University of Queensland at Gatton, an affiliate senior lecturer in the School of Chemistry & Molecular Biosciences at the University of Queensland at St. Lucia, and an investigator at the Australian Infectious Diseases Research Centre at the University of Queensland in St. Lucia, Australia
| | - Chris K Grant
- Sarah Kaye, BVSc, is a small animal clinician with the Animal Welfare League Qld Inc. in The Gold Coast, Queensland, Australia. Wenqi Wang, BVSc, PhD, is a postdoctoral fellow affiliated with the School of Veterinary Science at University of Queensland at Gatton in Australia. Craig Miller, DVM, is a postdoctoral fellow in the Department of Microbiology, Immunology & Pathology at Colorado State University in FortCollins, Colorado. Alicia McLuckie, BVSc, is a PhD candidate in the Faculty of Veterinary Science at the University of Sydney in NSW, Australia, Julia A. Beatty, BSc, BVetMed, PhD, FANZCVs (feline med), is a professor in the Faculty of Veterinary Science at the University of Sydney in NSW, Australia. Chris K. Grant, PhD, DSc, is founder and CEO of Custom Monoclonals International Corp. in West Sacramento, California. Sue VandeWoude, DVM, MS, DACLAM, is a professor in the Department of Microbiology, Immunology & Pathology at Colorado State University and Associate Dean for Research in the College of Veterinary & Biomedical Sciences at Colorado State University in Fort Collins, Colorado. Helle Bielefeldt-Ohmann, DVM, PhD, is a senior lecturer in the School of Veterinary Science at the University of Queensland at Gatton, an affiliate senior lecturer in the School of Chemistry & Molecular Biosciences at the University of Queensland at St. Lucia, and an investigator at the Australian Infectious Diseases Research Centre at the University of Queensland in St. Lucia, Australia
| | - Sue VandeWoude
- Sarah Kaye, BVSc, is a small animal clinician with the Animal Welfare League Qld Inc. in The Gold Coast, Queensland, Australia. Wenqi Wang, BVSc, PhD, is a postdoctoral fellow affiliated with the School of Veterinary Science at University of Queensland at Gatton in Australia. Craig Miller, DVM, is a postdoctoral fellow in the Department of Microbiology, Immunology & Pathology at Colorado State University in FortCollins, Colorado. Alicia McLuckie, BVSc, is a PhD candidate in the Faculty of Veterinary Science at the University of Sydney in NSW, Australia, Julia A. Beatty, BSc, BVetMed, PhD, FANZCVs (feline med), is a professor in the Faculty of Veterinary Science at the University of Sydney in NSW, Australia. Chris K. Grant, PhD, DSc, is founder and CEO of Custom Monoclonals International Corp. in West Sacramento, California. Sue VandeWoude, DVM, MS, DACLAM, is a professor in the Department of Microbiology, Immunology & Pathology at Colorado State University and Associate Dean for Research in the College of Veterinary & Biomedical Sciences at Colorado State University in Fort Collins, Colorado. Helle Bielefeldt-Ohmann, DVM, PhD, is a senior lecturer in the School of Veterinary Science at the University of Queensland at Gatton, an affiliate senior lecturer in the School of Chemistry & Molecular Biosciences at the University of Queensland at St. Lucia, and an investigator at the Australian Infectious Diseases Research Centre at the University of Queensland in St. Lucia, Australia
| | - Helle Bielefeldt-Ohmann
- Sarah Kaye, BVSc, is a small animal clinician with the Animal Welfare League Qld Inc. in The Gold Coast, Queensland, Australia. Wenqi Wang, BVSc, PhD, is a postdoctoral fellow affiliated with the School of Veterinary Science at University of Queensland at Gatton in Australia. Craig Miller, DVM, is a postdoctoral fellow in the Department of Microbiology, Immunology & Pathology at Colorado State University in FortCollins, Colorado. Alicia McLuckie, BVSc, is a PhD candidate in the Faculty of Veterinary Science at the University of Sydney in NSW, Australia, Julia A. Beatty, BSc, BVetMed, PhD, FANZCVs (feline med), is a professor in the Faculty of Veterinary Science at the University of Sydney in NSW, Australia. Chris K. Grant, PhD, DSc, is founder and CEO of Custom Monoclonals International Corp. in West Sacramento, California. Sue VandeWoude, DVM, MS, DACLAM, is a professor in the Department of Microbiology, Immunology & Pathology at Colorado State University and Associate Dean for Research in the College of Veterinary & Biomedical Sciences at Colorado State University in Fort Collins, Colorado. Helle Bielefeldt-Ohmann, DVM, PhD, is a senior lecturer in the School of Veterinary Science at the University of Queensland at Gatton, an affiliate senior lecturer in the School of Chemistry & Molecular Biosciences at the University of Queensland at St. Lucia, and an investigator at the Australian Infectious Diseases Research Centre at the University of Queensland in St. Lucia, Australia
| |
Collapse
|
12
|
Hosoi H, Imadome KI, Tamura S, Kuriyama K, Murata S, Yamashita Y, Mushino T, Oiwa T, Kobata H, Nishikawa A, Nakakuma H, Hanaoka N, Isobe Y, Ohshima K, Sonoki T. An Epstein-Barr virus susceptible immature T-cell line, WILL4, established from a patient with T-lymphoblastic lymphoma bearing CD21 and a clonal EBV genome. Leuk Res 2017; 55:1-5. [PMID: 28110206 DOI: 10.1016/j.leukres.2017.01.022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2016] [Accepted: 01/13/2017] [Indexed: 02/07/2023]
Abstract
We managed a patient with an Epstein-Barr virus-associated T-cell lymphoblastic lymphoma. Mediastinal tumor cells at initial admission were positive for CD4, CD8, and TdT. Interestingly, a lymph node at necropsy was compatible for a CD4-positive peripheral T-cell lymphoma without CD8 and TdT expression, suggesting a different phenotype from the mediastinal tumor. Tumor cells in pleural effusion continued to proliferate in in vitro and were designated as WILL4. WILL4 cells were positive for CD3, CD4, CD8, CD21, T-cell receptor (TcR) αβ, and TdT, indicating a similar phenotype to thymocytes. Southern blot analyses showed that the pleural tumor and WILL4 cells shared a TcR gene rearrangement, and that both contained a clonal EBV genome in an episomal form. RT-PCR showed that EBNA1 and LMP1 were expressed in the fresh tumor and WILL4 cells. Southern blot analyses revealed that WILL4 cells were susceptible to EBV infection in vitro using B95-8 supernatant. Anti-CD21 antibody inhibited in vitro infection of EBV, suggesting that CD21 plays a role in EBV infection into WILL4 cells. In vitro infection of EBV did not affect latent gene expression in WILL4 cells. WILL4 is a useful tool for analyzing the roles of EBV in onocogenesis in immature T-lymphoid malignancies.
Collapse
Affiliation(s)
- Hiroki Hosoi
- Hematology/Oncology, Wakayama Medical University, Japan
| | - Ken-Ichi Imadome
- Division of Advanced Medicine for Virus Infections, National Research Institute for Child Health and Development, Japan
| | - Shinobu Tamura
- Hematology/Oncology, Wakayama Medical University, Japan; Hematology and Oncology, Kinan Hospital, Japan
| | | | - Shogo Murata
- Hematology/Oncology, Wakayama Medical University, Japan
| | | | | | - Takehiro Oiwa
- Hematology/Oncology, Wakayama Medical University, Japan
| | | | | | | | | | - Yasushi Isobe
- Division of Hematology and Oncology, Department of Internal Medicine,St. Marianna University School of Medicine, Japan
| | - Kouichi Ohshima
- The First Department of Pathology, College of Medicine, Kurume University, Japan
| | - Takashi Sonoki
- Hematology/Oncology, Wakayama Medical University, Japan.
| |
Collapse
|
13
|
Olszewski AJ, Fallah J, Castillo JJ. Human immunodeficiency virus-associated lymphomas in the antiretroviral therapy era: Analysis of the National Cancer Data Base. Cancer 2016; 122:2689-97. [DOI: 10.1002/cncr.30112] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2016] [Revised: 02/10/2016] [Accepted: 02/16/2016] [Indexed: 11/11/2022]
Affiliation(s)
- Adam J. Olszewski
- Department of Medicine; Alpert Medical School of Brown University; Providence Rhode Island
| | - Jaleh Fallah
- Department of Medicine; Memorial Hospital of Rhode Island; Pawtucket Rhode Island
| | - Jorge J. Castillo
- Department of Medicine; Harvard Medical School; Boston Massachusetts
- Division of Hematologic Oncology, Dana-Farber Cancer Institute; Boston Massachusetts
| |
Collapse
|
14
|
De Paoli P, Carbone A. Microenvironmental abnormalities induced by viral cooperation: Impact on lymphomagenesis. Semin Cancer Biol 2015; 34:70-80. [DOI: 10.1016/j.semcancer.2015.03.009] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2014] [Revised: 02/10/2015] [Accepted: 03/19/2015] [Indexed: 01/01/2023]
|
15
|
The biology and treatment of plasmablastic lymphoma. Blood 2015; 125:2323-30. [PMID: 25636338 DOI: 10.1182/blood-2014-10-567479] [Citation(s) in RCA: 286] [Impact Index Per Article: 31.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2014] [Accepted: 01/28/2015] [Indexed: 12/17/2022] Open
Abstract
Plasmablastic lymphoma (PBL) is an aggressive lymphoma commonly associated with HIV infection. However, PBL can also be seen in patients with other immunodeficiencies as well as in immunocompetent individuals. Because of its distinct clinical and pathological features, such as lack of expression of CD20, plasmablastic morphology, and clinical course characterized by early relapses and subsequent chemotherapy resistance, PBL can represent a diagnostic and therapeutic challenge for pathologists and clinicians alike. Despite the recent advances in the therapy of HIV-associated and aggressive lymphomas, patients with PBL for the most part have poor outcomes. The objectives of this review are to summarize the current knowledge on the epidemiology, biology, clinical and pathological characteristics, differential diagnosis, therapy, prognostic factors, outcomes, and potential novel therapeutic approaches in patients with PBL and also to increase the awareness toward PBL in the medical community.
Collapse
|
16
|
EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management. Exp Mol Med 2015; 47:e132. [PMID: 25613729 PMCID: PMC4314582 DOI: 10.1038/emm.2014.82] [Citation(s) in RCA: 79] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2014] [Accepted: 10/01/2014] [Indexed: 12/12/2022] Open
Abstract
Epstein–Barr virus (EBV) is a ubiquitous herpesvirus, affecting >90% of the adult population. EBV targets B-lymphocytes and achieves latent infection in a circular episomal form. Different latency patterns are recognized based on latent gene expression pattern. Latent membrane protein-1 (LMP-1) mimics CD40 and, when self-aggregated, provides a proliferation signal via activating the nuclear factor-kappa B, Janus kinase/signal transducer and activator of transcription, phosphoinositide 3-kinase/Akt (PI3K/Akt) and mitogen-activated protein kinase pathways to promote cellular proliferation. LMP-1 also induces BCL-2 to escape from apoptosis and gives a signal for cell cycle progression by enhancing cyclin-dependent kinase 2 and phosphorylation of retinoblastoma (Rb) protein and by inhibiting p16 and p27. LMP-2A blocks the surface immunoglobulin-mediated lytic cycle reactivation. It also activates the Ras/PI3K/Akt pathway and induces Bcl-xL expression to promote B-cell survival. Recent studies have shown that ebv-microRNAs can provide extra signals for cellular proliferation, cell cycle progression and anti-apoptosis. EBV is well known for association with various types of B-lymphocyte, T-lymphocyte, epithelial cell and mesenchymal cell neoplasms. B-cell lymphoproliferative disorders encompass a broad spectrum of diseases, from benign to malignant. Here we review our current understanding of EBV-induced lymphomagenesis and focus on biology, diagnosis and management of EBV-associated B-cell lymphoproliferative disorders.
Collapse
|